India's drug regulator, CDSCO, cancelled the import license for QR678 Neo, an anti-hair loss product. The product, registered as a cosmetic, was promoted on its website as a treatment for conditions like post-chemotherapy hair loss and androgenetic alopecia. CDSCO cited this as a violation for making false and misleading claims, distinguishing between cosmetic products and drugs. The company described QR678 Neo as plant-derived peptides addressing hair fall and follicle density.